Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight
Some of the key facts of the Pediatric Obesity Market Report:
The Pediatric Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Novo Nordisk highlighted the effectiveness of its obesity treatment, Saxenda (liraglutide), in children under 12 through positive Phase III trial results. Participants receiving Saxenda experienced an average reduction of 5.8% in body mass index (BMI), whereas the placebo group saw a decrease of only 1.6%. The Phase III trial findings were presented at the European Association for the Study of Diabetes (EASD) conference in Spain.
In 2023, around 8 million children aged 5 to 19 were affected by obesity across the 7MM. With ongoing lifestyle trends, this figure is anticipated to rise substantially in the coming years.
Research indicates that the prevalence of overweight, including obesity, among children and adolescents aged 5–19 has surged from 8% in 1990 to 20% in 2022. This increase has been observed in both genders, with 19% of girls and 21% of boys classified as overweight in 2022.
Among the EU4 and the UK, Germany recorded the highest prevalence of childhood obesity cases, while Spain had the lowest.
Rhythm Pharmaceuticals intends to file a supplemental New Drug Application (sNDA) with the US FDA in Q2 2024 to extend IMCIVREE's label to include children aged 2 to 6 years
Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharma, Jack Yanovski, and others
Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others
The Pediatric Obesity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pediatric Obesity pipeline products will significantly revolutionize the Pediatric Obesity market dynamics.
Pediatric Obesity Overview
Pediatric obesity refers to the condition of having excess body fat in children and adolescents. It is a complex medical condition characterized by an abnormal or excessive accumulation of fat that may negatively affect a child's health and well-being.
Pediatric Obesity Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Pediatric Obesity Epidemiology Segmentation:
The Pediatric Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving Pediatric Obesity epidemiology trends @ Pediatric Obesity Epidemiology Forecast
Pediatric Obesity Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Obesity market or expected to get launched during the study period. The analysis covers Pediatric Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pediatric Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Pediatric Obesity Therapies and Key Companies
Scope of the Pediatric Obesity Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski, and others
Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others
Pediatric Obesity Therapeutic Assessment: Pediatric Obesity current marketed and Pediatric Obesity emerging therapies
Pediatric Obesity Market Dynamics: Pediatric Obesity market drivers and Pediatric Obesity market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Pediatric Obesity Unmet Needs, KOL's views, Analyst's views, Pediatric Obesity Market Access and Reimbursement
Table of Contents
1. Pediatric Obesity Market Report Introduction
2. Executive Summary for Pediatric Obesity
3. SWOT analysis of Pediatric Obesity
4. Pediatric Obesity Patient Share (%) Overview at a Glance
5. Pediatric Obesity Market Overview at a Glance
6. Pediatric Obesity Disease Background and Overview
7. Pediatric Obesity Epidemiology and Patient Population
8. Country-Specific Patient Population of Pediatric Obesity
9. Pediatric Obesity Current Treatment and Medical Practices
10. Pediatric Obesity Unmet Needs
11. Pediatric Obesity Emerging Therapies
12. Pediatric Obesity Market Outlook
13. Country-Wise Pediatric Obesity Market Analysis (2020–2034)
14. Pediatric Obesity Market Access and Reimbursement of Therapies
15. Pediatric Obesity Market Drivers
16. Pediatric Obesity Market Barriers
17. Pediatric Obesity Appendix
18. Pediatric Obesity Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight
DelveInsight's 'Pediatric Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pediatric Obesity, historical and forecasted epidemiology as well as the Pediatric Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Pediatric Obesity Market Report: The Pediatric Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In September 2024, Novo Nordisk highlighted the effectiveness of its obesity treatment, Saxenda (liraglutide), in children under 12 through positive Phase III trial results. Participants receiving Saxenda experienced an average reduction of 5.8% in body mass index (BMI), whereas the placebo group saw a decrease of only 1.6%. The Phase III trial findings were presented at the European Association for the Study of Diabetes (EASD) conference in Spain. In 2023, around 8 million children aged 5 to 19 were affected by obesity across the 7MM. With ongoing lifestyle trends, this figure is anticipated to rise substantially in the coming years. Research indicates that the prevalence of overweight, including obesity, among children and adolescents aged 5–19 has surged from 8% in 1990 to 20% in 2022. This increase has been observed in both genders, with 19% of girls and 21% of boys classified as overweight in 2022. Among the EU4 and the UK, Germany recorded the highest prevalence of childhood obesity cases, while Spain had the lowest. Rhythm Pharmaceuticals intends to file a supplemental New Drug Application (sNDA) with the US FDA in Q2 2024 to extend IMCIVREE's label to include children aged 2 to 6 years Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharma, Jack Yanovski, and others Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others The Pediatric Obesity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pediatric Obesity pipeline products will significantly revolutionize the Pediatric Obesity market dynamics. Pediatric Obesity Overview Pediatric obesity refers to the condition of having excess body fat in children and adolescents. It is a complex medical condition characterized by an abnormal or excessive accumulation of fat that may negatively affect a child's health and well-being. Pediatric Obesity Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Pediatric Obesity Epidemiology Segmentation: The Pediatric Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Pediatric Obesity epidemiology trends @ Pediatric Obesity Epidemiology Forecast Pediatric Obesity Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Obesity market or expected to get launched during the study period. The analysis covers Pediatric Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Pediatric Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Pediatric Obesity Therapies and Key Companies Scope of the Pediatric Obesity Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski, and others Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others Pediatric Obesity Therapeutic Assessment: Pediatric Obesity current marketed and Pediatric Obesity emerging therapies Pediatric Obesity Market Dynamics: Pediatric Obesity market drivers and Pediatric Obesity market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Pediatric Obesity Unmet Needs, KOL's views, Analyst's views, Pediatric Obesity Market Access and Reimbursement Table of Contents 1. Pediatric Obesity Market Report Introduction 2. Executive Summary for Pediatric Obesity 3. SWOT analysis of Pediatric Obesity 4. Pediatric Obesity Patient Share (%) Overview at a Glance 5. Pediatric Obesity Market Overview at a Glance 6. Pediatric Obesity Disease Background and Overview 7. Pediatric Obesity Epidemiology and Patient Population 8. Country-Specific Patient Population of Pediatric Obesity 9. Pediatric Obesity Current Treatment and Medical Practices 10. Pediatric Obesity Unmet Needs 11. Pediatric Obesity Emerging Therapies 12. Pediatric Obesity Market Outlook 13. Country-Wise Pediatric Obesity Market Analysis (2020–2034) 14. Pediatric Obesity Market Access and Reimbursement of Therapies 15. Pediatric Obesity Market Drivers 16. Pediatric Obesity Market Barriers 17. Pediatric Obesity Appendix 18. Pediatric Obesity Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
National Post
a day ago
- National Post
Yagi & Co., Ltd.: FUJILOOM™ Blankets, Mats, and Throw Towels Are Made with "LAVATECH™" Containing Lava from Mt. Fuji to Be First Exhibited at SUPERZOO 2025
Article content Crafted for Calm, Rooted in Nature, Backed by Science Article content TOKYO — Yagi & Co., Ltd. (TOKYO:7460) ( will unveil FUJILOOM for the first time at the SUPERZOO Exhibition in USA (North America's largest pet product marketplace). Article content Yagi & Co., Ltd.: FUJILOOM™ blankets, mats, and throw towels are made with 'LAVATECH™' containing Lava from Mt. Fuji to be first Exhibited at SUPERZOO 2025. Article content About FUJILOOM Article content Developed by YAGI, a heritage textile innovator from Japan since 1893, FUJILOOM merges over 130 years of fiber expertise with modern pet wellness needs. Crafted with natural volcanic minerals sourced from Mt. Fuji, our collection supports restful sleep and overall well-being. FUJILOOM blankets, mats, and throw towels are made with LAVATECH™, our proprietary far-infrared textile technology. Soft, breathable, and scientifically developed, each piece is designed to support your pet's comfort, sleep quality, and emotional calm. Whether at home or on the go, FUJILOOM elevates everyday pet life with natural function, thoughtful design, and Japanese craftsmanship. Article content About LAVATECH Article content Since ancient times, the lava rock formed beneath Mt. Fuji has been carefully protected from changes in surface temperature and weathering. LAVATECH is made by weaving this high-quality underground lava rock. We have achieved a high far-infrared effect by using a special technology to finely crush the lava rock that lies underground at Mt. Fuji for weaving into fibers. This brand of materials enables the creation of new products that address a wide range of health issues in areas such as sleep, beauty and sports through their blood circulation-promoting effects. Article content LAVATECH official website: Article content Article content About YAGI Article content Founded in 1893, Yagi & Co., Ltd. is a leading company in textiles, apparel, lifestyle goods, and international brands, both in Japan and around the world. With approximately 83.3 billion yen in global revenue, the company is listed on the Tokyo Stock Exchange. Yagi is committed to its social and environmental responsibilities, guided by its philosophy of 'Consistent Sincerity.' For more information about Yagi, please visit Article content Article content Future developments Article content The Yagi Group's VISION is to unlock the potential of textiles through innovation to realize a sustainable society. We engage in various activities, with the key words of sustainable and global representing the basic strategies of our medium-term management plan. Through the development of FUJILOOM, we will work to achieve the following. Article content Article content Yagi & Co., Ltd. Article content Article content Staff in charge: Haruka Tsuji Article content Article content MAIL: Article content fujiloom@ Article content Article content Article content Article content View source version on Article content Article content Contacts
Globe and Mail
a day ago
- Globe and Mail
Novo Nordisk Reports Strong H1 2025 Performance
Novo Nordisk ( (NVO)) has released its Q2 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Novo Nordisk is a leading global healthcare company specializing in diabetes care, obesity care, and rare diseases, with a strong focus on innovation and sustainability. In the first half of 2025, Novo Nordisk reported a significant increase in sales and operating profit, driven by strong performance in its obesity care segment and GLP-1 diabetes treatments. The company's sales grew by 16% in Danish kroner and 18% at constant exchange rates, reaching DKK 154.9 billion, while operating profit increased by 25% in Danish kroner and 29% at constant exchange rates to DKK 72.2 billion. The US and International Operations both contributed to this growth, with notable increases in obesity care sales, particularly for Wegovy®. Novo Nordisk also made strategic advancements in its research and development, including progressing weight management treatments into phase 3 development and submitting new drug applications in the EU. Despite these achievements, the company has adjusted its full-year outlook due to lower growth expectations for its GLP-1 treatments in the second half of 2025, influenced by market dynamics and competition. Looking ahead, Novo Nordisk remains committed to maximizing growth opportunities under new leadership, with a continued focus on expanding its product portfolio and market reach.
